| Disease ID | Disease name | Source of annotation with MAP2K2 | OMIM link | Number of associated genes | genes |
|---|---|---|---|---|---|
| PS115150 | CARDIOFACIOCUTANEOUS SYNDROME | ClinVar, OMIM, HUMSAVAR | link to OMIM | 4 | KRAS, BRAF, MAP2K1, MAP2K2 |
Download the gene annotation in CSV format
| KEGG pathway | KEGG ID | KEGG IC |
|---|---|---|
| Melanoma | hsa05218 | 6.56 |
| Bladder cancer | hsa05219 | 7.38 |
| cGMP-PKG signaling pathway | hsa04022 | 5.32 |
| Natural killer cell mediated cytotoxicity | hsa04650 | 5.53 |
| Chronic myeloid leukemia | hsa05220 | 6.48 |
| Thyroid cancer | hsa05216 | 7.48 |
| Signaling pathways regulating pluripotency of stem cells | hsa04550 | 5.6 |
| cAMP signaling pathway | hsa04024 | 5.05 |
| Prostate cancer | hsa05215 | 6.11 |
| Long-term potentiation | hsa04720 | 6.64 |
| Neurotrophin signaling pathway | hsa04722 | 5.78 |
| Central carbon metabolism in cancer | hsa05230 | 6.7 |
| Choline metabolism in cancer | hsa05231 | 6.09 |
| FoxO signaling pathway | hsa04068 | 5.63 |
| HIF-1 signaling pathway | hsa04066 | 5.9 |
| Oxytocin signaling pathway | hsa04921 | 5.4 |
| ErbB signaling pathway | hsa04012 | 6.15 |
| Insulin signaling pathway | hsa04910 | 5.55 |
| Prion diseases | hsa05020 | 7.48 |
| Endometrial cancer | hsa05213 | 6.81 |
| Influenza A | hsa05164 | 5.21 |
| PI3K-Akt signaling pathway | hsa04151 | 4.21 |
| Hepatitis B | hsa05161 | 5.52 |
| Vascular smooth muscle contraction | hsa04270 | 5.74 |
| Renal cell carcinoma | hsa05211 | 6.6 |
| Gap junction | hsa04540 | 6.24 |
| VEGF signaling pathway | hsa04370 | 6.77 |
| Proteoglycans in cancer | hsa05205 | 5.02 |
| Estrogen signaling pathway | hsa04915 | 6.11 |
| MicroRNAs in cancer | hsa05206 | 5.38 |
| Toll-like receptor signaling pathway | hsa04620 | 6.0 |
| Pathways in cancer | hsa05200 | 3.98 |
| GnRH signaling pathway | hsa04912 | 6.18 |
| B cell receptor signaling pathway | hsa04662 | 6.52 |
| Ras signaling pathway | hsa04014 | 4.9 |
| Melanogenesis | hsa04916 | 5.97 |
| Glioma | hsa05214 | 6.66 |
| Acute myeloid leukemia | hsa05221 | 6.74 |
| MAPK signaling pathway | hsa04010 | 4.63 |
| Thyroid hormone signaling pathway | hsa04919 | 5.82 |
| Long-term depression | hsa04730 | 6.74 |
| Regulation of actin cytoskeleton | hsa04810 | 4.9 |
| T cell receptor signaling pathway | hsa04660 | 6.01 |
| Non-small cell lung cancer | hsa05223 | 6.88 |
| Rap1 signaling pathway | hsa04015 | 4.97 |
| Fc epsilon RI signaling pathway | hsa04664 | 6.6 |
| Prolactin signaling pathway | hsa04917 | 6.6 |
| REACTOME pathway | REACTOME ID | REACTOME IC |
|---|---|---|
| Signal transduction by L1 | R-HSA-445144 | 8.59 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 4.85 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 4.26 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 4.9 |
| Signaling by Interleukins | R-HSA-449147 | 4.71 |
| Signaling by Leptin | R-HSA-2586552 | 5.1 |
| Frs2-mediated activation | R-HSA-170968 | 5.12 |
| MAP2K and MAPK activation | R-HSA-5674135 | 7.66 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 3.74 |
| IGF1R signaling cascade | R-HSA-2428924 | 4.85 |
| Signaling by FGFR3 | R-HSA-5654741 | 4.69 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 4.85 |
| Signaling by ERBB4 | R-HSA-1236394 | 4.7 |
| Innate Immune System | R-HSA-168249 | 3.17 |
| IRS-mediated signalling | R-HSA-112399 | 4.87 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 5.11 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 4.71 |
| RAF activation | R-HSA-5673000 | 8.34 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 5.15 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 4.71 |
| MAPK family signaling cascades | R-HSA-5683057 | 4.89 |
| Signalling by NGF | R-HSA-166520 | 4.23 |
| Signaling by VEGF | R-HSA-194138 | 4.66 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 5.12 |
| Developmental Biology | R-HSA-1266738 | 3.48 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 4.32 |
| Signaling by EGFR | R-HSA-177929 | 4.59 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 5.14 |
| SOS-mediated signalling | R-HSA-112412 | 5.15 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 5.14 |
| Disease | R-HSA-1643685 | 3.33 |
| Signaling by Insulin receptor | R-HSA-74752 | 4.73 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 4.71 |
| Insulin receptor signalling cascade | R-HSA-74751 | 4.85 |
| Signaling by FGFR4 | R-HSA-5654743 | 4.69 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 8.46 |
| Infectious disease | R-HSA-5663205 | 4.47 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 4.7 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 5.15 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 5.09 |
| L1CAM interactions | R-HSA-373760 | 6.19 |
| Signaling by FGFR | R-HSA-190236 | 4.67 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 4.03 |
| Immune System | R-HSA-168256 | 2.37 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 4.71 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 5.14 |
| Signaling by SCF-KIT | R-HSA-1433557 | 4.73 |
| Interleukin-2 signaling | R-HSA-451927 | 5.05 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 5.15 |
| Signaling by ERBB2 | R-HSA-1227986 | 4.66 |
| Signalling to RAS | R-HSA-167044 | 5.08 |
| DAP12 signaling | R-HSA-2424491 | 4.64 |
| Interleukin-3, 5 and GM-CSF signaling | R-HSA-512988 | 4.99 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 10.4 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 8.28 |
| Signaling by FGFR1 | R-HSA-5654736 | 4.69 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 5.15 |
| NGF signalling via TRKA from the plasma membrane | R-HSA-187037 | 4.51 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 5.14 |
| Prolonged ERK activation events | R-HSA-169893 | 5.11 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 7.66 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 9.66 |
| Signaling by GPCR | R-HSA-372790 | 2.68 |
| Signaling by FGFR2 | R-HSA-5654738 | 4.68 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 5.15 |
| Signalling to ERKs | R-HSA-187687 | 5.04 |
| ARMS-mediated activation | R-HSA-170984 | 5.12 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 9.81 |
| DAP12 interactions | R-HSA-2172127 | 4.56 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 5.15 |
| Signaling by PDGF | R-HSA-186797 | 4.53 |
| Axon guidance | R-HSA-422475 | 3.93 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 5.07 |
| Signal Transduction | R-HSA-162582 | 1.78 |
| Downstream signal transduction | R-HSA-186763 | 4.65 |
| GO term | GO ID | GO IC |
|---|---|---|
| binding | GO:0005488 | 0.18 |
| kinase regulator activity | GO:0019207 | 4.5 |
| purine ribonucleoside triphosphate binding | GO:0035639 | 2.22 |
| kinase activator activity | GO:0019209 | 5.58 |
| protein complex scaffold | GO:0032947 | 5.5 |
| signal transducer activity | GO:0004871 | 2.28 |
| nucleotide binding | GO:0000166 | 1.96 |
| heterocyclic compound binding | GO:1901363 | 1.06 |
| purine nucleoside binding | GO:0001883 | 2.22 |
| nucleoside binding | GO:0001882 | 2.21 |
| cation binding | GO:0043169 | 1.4 |
| molecular function regulator | GO:0098772 | 2.51 |
| receptor signaling protein activity | GO:0005057 | 4.76 |
| ion binding | GO:0043167 | 1.36 |
| protein serine/threonine kinase activity | GO:0004674 | 3.64 |
| transferase activity | GO:0016740 | 1.95 |
| protein serine/threonine/tyrosine kinase activity | GO:0004712 | 6.07 |
| protein tyrosine kinase activity | GO:0004713 | 4.54 |
| ribonucleoside binding | GO:0032549 | 2.22 |
| purine nucleotide binding | GO:0017076 | 2.19 |
| protein kinase activity | GO:0004672 | 3.27 |
| metal ion binding | GO:0046872 | 1.41 |
| ATP binding | GO:0005524 | 2.43 |
| structural molecule activity | GO:0005198 | 3.1 |
| protein kinase regulator activity | GO:0019887 | 4.6 |
| enzyme regulator activity | GO:0030234 | 2.85 |
| kinase activity | GO:0016301 | 2.93 |
| nucleoside phosphate binding | GO:1901265 | 1.96 |
| small molecule binding | GO:0036094 | 1.89 |
| catalytic activity | GO:0003824 | 1.05 |
| PDZ domain binding | GO:0030165 | 5.22 |
| protein domain specific binding | GO:0019904 | 3.32 |
| protein kinase activator activity | GO:0030295 | 5.68 |
| protein serine/threonine kinase activator activity | GO:0043539 | 6.91 |
| adenyl ribonucleotide binding | GO:0032559 | 2.41 |
| adenyl nucleotide binding | GO:0030554 | 2.4 |
| carbohydrate derivative binding | GO:0097367 | 2.03 |
| organic cyclic compound binding | GO:0097159 | 1.05 |
| receptor signaling protein serine/threonine kinase activity | GO:0004702 | 5.23 |
| purine ribonucleoside binding | GO:0032550 | 2.22 |
| phosphotransferase activity, alcohol group as acceptor | GO:0016773 | 3.08 |
| scaffold protein binding | GO:0097110 | 5.93 |
| protein binding | GO:0005515 | 0.46 |
| transferase activity, transferring phosphorus-containing groups | GO:0016772 | 2.77 |
| purine ribonucleotide binding | GO:0032555 | 2.2 |
| MAP kinase kinase activity | GO:0004708 | 7.25 |
| ribonucleotide binding | GO:0032553 | 2.19 |
| enzyme activator activity | GO:0008047 | 3.56 |